DexCom (DXCM) does not expect a material impact from the FDA’s warning letter to its manufacturing capacity or its fiscal year 2025 guidance for revenue previously issued on February 13.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- Wells sees no material impact from DexCom warning letter
- DexCom warning letter ‘not thesis changing,’ says BofA
- Dexcom’s Resilience Amid FDA Warning: Buy Rating Affirmed by Analyst
- DexCom falls 7% to $71.99 after receiving warning letter from FDA
- DexCom receives warning letter from FDA, sees no impact to FY25 guidance